The main focus of our research is to elucidate cellular signals that regulate the hability of our immune system to control diseases such as cancer and inflammatory diseases.

We have made important contributions to immunology research including interaction of immune cells with the tumour microenviroment and identification of factors that regulate their natural anti-cancer responses.

Our goal is to identify new regulatory elements that prevents the immune system, particularly Natural Killer (NK) lymphocytes to control disease progression. And our work spans the broad areas of cell signaling, immunotherapy, inflammation, among others.

We envision awakening the cure inside us, aiming to discover how to activate and maximise the immunologal responses using the patient’s own immune system.

Thanks to our funding our most recent achievements elucidated the relative contribution of different members of the TGF-beta superfamily in regulating NK cell functions during homeostasis and disease.

Our projects use a multidisciplinary approach, bringing together contemporary techniques in cancer biology, cellular and molecular biology, pharmacology, proteomics and immunology/immunotherapy. We use cutting edge models to: mimic disease, validate our discovers, elucidate mechanisms of action and tailor novel therapeutic approaches. Our research elucidates the cellular signaling and mechanism of regulation of innate lymphocites, and how manipulating these pathways would allow their maximum effectiveness to control different diseases.

Our current research projects aim to:

  • Use computational and system biology to identify new regulatory elements in cellular signalling of immune cells
  • Identify and understand novel immune checkpoints
  • Tailor immunotherapies to modulate immune responses in cancer and inflammatory diseases.

Student projects

We have research interests in, but are not restricted to:

  • Systems biology to identify new regulatory elements in cellular signalling of immune cells
  • Identifying and understanding novel immune checkpoints
  • Tailoring immunotherapies to modulate immune responses in cancer and inflammatory diseases
  • Development of novel pre-clinical models to mimic and study novel therapeutic targets for human disease

We have collaborated with various academic research groups, clinicians and industry partners within our large collaborative network in Australia and overseas on a variety of basic or translational reseach projects. We have received funding from Cure Cancer Australia (who awarded Dr. Guimaraes as the 2019 Researcher of the Year), Innovations Connections, NBCF, NHMRC, and WEWC.

Funding

We have proudly received funding from:

  • Priority-Driven Collaborative Cancer Research Scheme (PdCCRS) from the Cure Cancer Australia
  • National Health and Medical Research Council
  • National Breast Cancer Foundation
  • Innovation Connection Grant
  • Brazil CAPES/PrInt Program

Collaborators

We have collaborations and support of scientist from the follow institutions:

A*STAR (Singapore), CIML (France), CRCL (France), Keio University (Japan), Institute Pasteur (France), Mater Research (Australia), MSKCC (USA), Monash University (Australia), ONJCC (Australia), Royal Melbourne Hospital (Australia), Shanghai Institute of Immunology (China) Thomas Jefferson University (USA),VCCC (Australia), WEHI (Australia), UFPR (Brazil), Unicamp (Brazil), University of Hong Kong (Hong Kong), University of Melbourne (Australia).